Institutionalizing Real-World Evidence

As real-world evidence (RWE) becomes vital in drug development and commercialization, life sciences organizations face challenges in managing vast, diverse, and rapidly growing healthcare data. Traditional clinical trials lack the scale and variability that real-world data (RWD) from sources like EHRs, claims, wearables, and social media provide. However, many organizations struggle with fragmented analytics environments, siloed tools, inconsistent workflows, and manual processes. These inefficiencies hinder timely insights and cross-functional collaboration across R&D, commercial, and health economics teams.

To institutionalize RWE, organizations must build a unified data architecture, adopt common data standards, implement reusable analytics templates, and enable self-service analytics. A tightly integrated ecosystem—such as the close coupling of SAS and Hadoop—can support high-volume ingestion, standardized cohort definitions, and advanced analytics to deliver scalable insights faster and more accurately.

Download the full whitepaper to explore best practices for building a robust, enterprise-wide RWE strategy that enhances patient outcomes and operational efficiency.